首页> 美国卫生研究院文献>Journal of Radiation Research >Clinical experience of pelvic radiotherapy or chemoradiotherapy for postoperative uterine cervical cancer using intensity-modulated radiation therapy
【2h】

Clinical experience of pelvic radiotherapy or chemoradiotherapy for postoperative uterine cervical cancer using intensity-modulated radiation therapy

机译:调强放射治疗盆腔放疗或放化疗治疗术后子宫颈癌的临床经验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The purpose of this study was to reveal treatment outcomes and toxicity after pelvic intensity-modulated radiotherapy (IMRT) for postoperative uterine cervical cancer of Japanese patients. Consecutive patients who were treated with pelvic IMRT for postoperative cervical cancer in our institute were retrospectively analyzed. Relapse-free survival (RFS) and overall survival (OS) were calculated using the Kaplan–Meier estimator, and log-rank tests were used to compare differences. From the database, 62 patients were identified. The pathology was squamous cell carcinoma in 44 patients and other pathology in 18 patients. Of the 62 patients, 35 had high-risk prognostic factors and 27 patients had intermediate-risk prognostic factors. The prescribed radiation doses were 50 Gy in 25 fractions for 58 patients and 50.4 Gy in 28 fractions for 4 patients. One patient received a vaginal cuff boost. Chemotherapy was administered in 36 patients. During the median follow-up period of 50.9 months, there was no locoregional failure. Six patients in the high-risk group relapsed, but none of the patients in the intermediate-risk group relapsed (  = 0.02). The 3-year OS and RFS rates were 98.2% and 90.9%, respectively. Significant factors related to RFS were squamous cell carcinoma pathology (  = 0.02), pathological T stage (  = 0.04), surgical margin status (  P
机译:这项研究的目的是揭示骨盆调强放疗(IMRT)对日本患者术后宫颈癌的治疗效果和毒性。回顾性分析本院接受盆腔IMRT治疗的宫颈癌术后患者。使用Kaplan-Meier估计器计算无复发生存期(RFS)和总生存期(OS),并使用对数秩检验比较差异。从数据库中识别出62名患者。病理为鳞状细胞癌44例,其他病理18例。在62例患者中,有35例具有高风险预后因素,而27例具有中度预后因素。 58位患者的规定放射剂量为25分数的50 Gy,4位患者为28分数的50.4 Gy。一名患者接受了阴道套囊强化治疗。对36名患者进行了化学疗法。在50.9个月的中位随访期内,没有局部区域性衰竭。高危组中有6例患者复发,但中危组中无患者复发(= 0.02)。 3年OS和RFS率分别为98.2%和90.9%。与RFS相关的重要因素是鳞状细胞癌病理(= 0.02),病理T期(= 0.04),手术切缘状态(P

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号